The ALiAS Trial: Examining the potential for lithium treatment to help patients with suicidality

Phase 4

Recruiting

• Conditions: Suicidality; Mental Health - Suicide

• Registration Number: ACTRN12618000106235
• Lead Sponsor: The University of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-01-24
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Participants will be eligible to take part in the ALiAS Trial if they are:
- Aged 18-65 years
- Meet DSM-5 criteria for a mood disorder
- Currently receiving treatment for a mood disorder
- Presenting with suicidality as defined by a score of greater than 8 on the S-STS scale
- Not currently receiving lithium treatment and their treating doctor does not intend to prescribe lithium during the course of the study
- Willing and able to comply to the trial protocol in English
- Willing and able to give written informed consent in English

Exclusion Criteria

Participants will be not be eligible to take part in the ALiAS Trial if they:
- Are not receiving treatment for a mood disorder
- Have used lithium in the past 6 months
- Meet criteria for personality disorder or substance dependency disorder in accordance with DSM-5 criteria
- Have contraindication for lithium therapy including heart conditions, thyroid, hepatic, renal dysfunction (as checked by blood tests)
- Are pregnant (as checked by blood test) or breastfeeding or are of child-bearing potential and not willing to use effective contraception
- Have participated in another research trial involving an investigational medical product in the past 12 weeks

Study & Design

• Study Type: Interventional
• Study Design: Not specified